Bisoprolol: Nursing Drug Guide, Bradycardia & Hold Rules
Cardioselective beta-1 blocker for hypertension—and often stable heart failure per local cardiology protocols: the bedside priority is apical pulse and blood pressure before every dose. Bradycardia, hypotension, and heart block can develop or worsen during titration, and abrupt withdrawal can trigger severe angina, myocardial infarction, or arrhythmias even without known coronary disease.
Bisoprolol blocks beta-1 receptors, slowing heart rate and reducing contractility. The worst realistic failures are symptomatic bradycardia, hypotension, and second- or third-degree heart block—especially with digoxin, verapamil, or diltiazem on the MAR. Abrupt discontinuation can worsen angina or cause myocardial infarction or ventricular arrhythmias; labeling advises tapering over about one week even without overt coronary disease. Nurses must count apical pulse for a full minute, check blood pressure before each dose, hold when out of range, and coordinate prescriber-guided tapering—never stop because blood pressure looks normal.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Count apical pulse for a full minute and check blood pressure before every bisoprolol dose. Hold when heart rate or blood pressure fall below prescriber or protocol limits, and coordinate a taper over about one week when stopping—abrupt withdrawal can worsen angina or cause myocardial infarction even in patients treated only for hypertension.
Most common brand names
Bisoprolol fumarate is available generically and was marketed in the United States as Zebeta (oral tablets). Combination product Ziac (and other bisoprolol–hydrochlorothiazide formulations) pairs bisoprolol with a thiazide diuretic—verify whether the MAR lists single-entity bisoprolol or the combination to avoid duplicate beta-blocker or diuretic therapy.
Always confirm strength (2.5 mg, 5 mg, or 10 mg) and that the patient is not receiving a second beta blocker from another prescriber or home medication list.
| Product | Components | Nursing verification |
|---|---|---|
| Zebeta / generic | Bisoprolol fumarate alone | Match tablet strength to order; once-daily schedule |
| Ziac (and generics) | Bisoprolol + hydrochlorothiazide | Monitor potassium, sodium, orthostatic BP; avoid duplicate thiazide |
| Generic bisoprolol | Bisoprolol fumarate alone | Same hold and taper rules; confirm manufacturer leaflet if enteral tube crushing needed |
On a small screen, swipe or scroll sideways to see the full table.
Why we give it — Indications
Bisoprolol is a cardioselective beta-1 adrenergic blocker. U.S. prescribing information lists hypertension as the labeled indication; in many regions it is also titrated in stable heart failure per cardiology protocols—always follow the active order and institutional pathway.
| Use | Detail |
|---|---|
| Hypertension | May be used alone or with other antihypertensive agents per labeling. |
| Angina / ischemic heart disease | Often prescribed when myocardial oxygen demand must be lowered; abrupt withdrawal can worsen angina or precipitate myocardial infarction. |
| Stable heart failure (regional practice) | Not a labeled U.S. indication in reviewed Zebeta labeling, but widely used in compensated failure with careful titration—watch for decompensation. |
| Not a primary vasodilator | Does not replace ACE inhibitors, ARBs, or calcium channel blockers ordered for other mechanisms—verify each antihypertensive on the MAR |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Bisoprolol competitively blocks beta-1 adrenergic receptors, decreasing heart rate and contractility. Reduced myocardial oxygen demand supports angina control; lower cardiac output contributes to antihypertensive action. Beta-1 selectivity is not absolute—at higher doses or in susceptible patients, beta-2 effects (bronchospasm, masking of hypoglycemia symptoms) can still occur. Assess lungs and glucose trends in patients with asthma or type 2 diabetes.
| Physiologic effect | Clinical result | Nursing implication |
|---|---|---|
| ↓ Heart rate | Bradycardia, fatigue | Full-minute apical pulse before every dose |
| ↓ Contractility | Reduced cardiac output | Monitor BP and perfusion; caution in heart failure |
| ↓ Renin release | Lower BP | Expect gradual effect over 1–2 weeks—not immediate |
| ↓ AV nodal conduction | Heart block risk with nodal drugs | Hold for new block; review digoxin and CCB orders |
| Possible beta-2 blockade at high dose | Bronchospasm; masked hypoglycemia | Respiratory assessment; glucose monitoring in diabetes |
On a small screen, swipe or scroll sideways to see the full table.
Dosing overview
Dosing depends on indication, renal/hepatic function, and response. Verify each order against current prescribing information and institutional protocols.
Heart failure titration (when ordered per local protocol): Follow institution-specific heart-failure beta-blocker pathways and the current prescriber order. Do not assume outpatient hypertension starting doses apply to in-hospital up-titration.
| Scenario | Typical approach (labeling summary) | Nursing note |
|---|---|---|
| Hypertension — inadequate response at 5 mg | Increase to 10 mg once daily | Recheck pulse and BP before dose escalation |
| Hypertension — still inadequate at 10 mg | May increase to 20 mg once daily | Maximum reviewed labeling dose is 20 mg/day |
| Reactive airways | Start 2.5 mg once daily | Use lowest dose; monitor for wheezing |
| CrCl <40 mL/min or hepatic impairment | Initial 2.5 mg/day; cautious titration | Half-life prolonged in renal impairment per labeling |
| Older adult | Same starting doses unless renal/hepatic dysfunction | Fall precautions if dizziness; orthostatic BP checks |
| Discontinuation | Taper over ~1 week when stopping | Document taper; teach patient not to stop abruptly |
On a small screen, swipe or scroll sideways to see the full table.
Missed dose: Not specified in the reviewed prescribing information for a single missed dose. Do not double doses. Contact prescriber or pharmacist if multiple doses are missed, especially with ischemic heart disease, because abrupt interruption increases angina and arrhythmia risk.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset (antihypertensive) | Blood pressure reductions seen within one week of treatment per labeling | Do not repeat or stack doses for same-day effect |
| Peak effect | Plasma levels peak 2–4 hours after oral dosing; steady state within 5 days of once-daily dosing | Assess vitals on the routine schedule—not only immediately post-dose |
| Duration | Once-daily dosing supported by prolonged beta blockade | Missed doses matter for withdrawal risk; clarify taper if therapy interrupted |
| Half-life | Plasma elimination half-life 9–12 hours (longer in elderly and renal impairment) | Start 2.5 mg when CrCl <40 mL/min; trend renal function with basic metabolic panel |
| Excretion | Approximately 50% renal and 50% non-renal pathways; limited data suggest not dialyzable | Reduce initial dose in renal or hepatic impairment; pharmacy review when eGFR declines |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Apical pulse for a full minute and blood pressure (supine and standing when orthostasis is a concern)
- 12-lead ECG or rhythm strip if history of heart block, syncope, or new palpitations
- Renal and hepatic function for dose limits (creatinine clearance <40 mL/min or hepatic impairment)
- Perform medication reconciliation for other beta blockers, calcium channel blockers, and nodal agents
Contraindications
- Cardiogenic shock, overt cardiac failure, second- or third-degree AV block, marked sinus bradycardia per labeling
- Known hypersensitivity to bisoprolol fumarate or formulation excipients
- Untreated pheochromocytoma (labeling requires alpha blockade before beta blockade when applicable)
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Digoxin | Additive slowing of AV conduction; bradycardia risk | Monitor pulse and rhythm closely; hold per parameters and notify prescriber for new bradyarrhythmia |
| Diltiazem / verapamil / other nodal drugs | Increased risk of bradycardia and heart block per labeling | Verify orders; trend vitals; escalate symptomatic hypotension or block |
| Insulin / oral hypoglycemics | May mask tachycardia and tremor during hypoglycemia in type 2 diabetes | Teach glucose monitoring; do not rely on adrenergic warning signs alone |
| Sympathomimetics (e.g., epinephrine for anaphylaxis) | High beta-1 blockade may blunt bronchodilator response; unopposed alpha effects possible | Document beta-blocker use; follow anaphylaxis protocol and prescriber guidance |
On a small screen, swipe or scroll sideways to see the full table.
Asthma / reactive airways: Labeling states patients with bronchospastic disease should generally not receive beta-blockers; bisoprolol may be used with caution at the lowest dose (2.5 mg start) when alternatives are not tolerated—still monitor for bronchospasm.
Perioperative and anesthesia considerations
Chronic beta-blocker therapy should not be stopped abruptly before surgery per many guidelines, but the anesthesiologist must know the patient takes bisoprolol. Myocardial depressant anesthetics increase bradycardia and hypotension risk—document beta-blocker use on preoperative checklists. Epinephrine for anaphylaxis may be less effective; follow facility anaphylaxis protocol.
When bisoprolol is discontinued, labeling advises tapering over approximately one week with careful observation—even without overt coronary artery disease. In CAD, abrupt cessation can worsen angina or cause myocardial infarction or ventricular arrhythmias. Clarify taper orders on discharge; teach patients not to stop when blood pressure looks normal.
Administration
Route: Oral tablets once daily (morning or evening per order—consistency matters for blood pressure rhythm).
- May be taken with or without food per most formulations; swallow whole unless pharmacy approves splitting for specific products
- Do not crush extended-release products if dispensed—verify formulation
- Give at the same time each day when possible to maintain steady beta blockade
- If the patient cannot swallow, consult pharmacy for liquid alternatives or enteral tube compatibility—do not crush tablets without pharmacy approval
- Bedside identification: confirm Zebeta/generic versus Ziac before administration; combination tablets include hydrochlorothiazide
| Administration step | Action |
|---|---|
| Before dose | Apical pulse (60 seconds), blood pressure, compare to hold parameters, review MAR for duplicate beta blockers |
| During pass | Right patient, drug, dose, route, time; educate if pulse is borderline |
| After dose | Reassess orthostatic symptoms if hypotension risk; document hold or administration with vital signs |
| Discharge | Teach taper if discontinuing; provide refill plan; warn against stopping when BP improves |
On a small screen, swipe or scroll sideways to see the full table.
Expected therapeutic response
- Gradual reduction in resting heart rate and blood pressure toward prescriber targets
- Decreased frequency or severity of angina episodes when used for coronary artery disease
- Patient reports improved exercise tolerance without presyncope—if dizziness or fatigue worsen, reassess dose and hold parameters
Red flags — Stop and act
Bradycardia and conduction delay can progress to hemodynamic collapse. Abrupt withdrawal in ischemic heart disease is equally dangerous.
- Heart rate below prescriber hold limit, new second- or third-degree AV block, or pauses on monitor
- Symptomatic hypotension, syncope, or cold clammy extremities after dose
- Wheezing or bronchospasm in reactive airway disease—hold and escalate respiratory pathway
- Rest angina, crushing chest pain, or diaphoresis after missed doses or self-discontinuation—treat as acute coronary syndrome per protocol
- Signs of heart failure decompensation (crackles, weight gain, orthopnea) in patients with reduced ejection fraction
- Depression, confusion, or nightmares newly reported after dose increase—notify prescriber for mental status review
- Peripheral cyanosis or pain in fingers/toes suggesting severe beta-blockade—urgent perfusion assessment
Adverse effects
| Adverse effect | Frequency / notes | Nursing response |
|---|---|---|
| Bradycardia | Common; dose-related | Hold dose, notify prescriber, obtain rhythm strip; prepare for pacing pathway if symptomatic |
| Hypotension / dizziness | Common early in therapy or after dose increase | Assist with position changes; hold per parameters; monitor orthostatics |
| Fatigue, depression, sleep disturbance | Reported in beta-blocker class | Assess functional impact; notify prescriber if limits ADLs |
| Bronchospasm | Less common with cardioselective agent; still possible | Hold drug; bronchodilator therapy per prescriber; document allergy/intolerance |
| Masked hypoglycemia symptoms | Class effect in diabetes | Emphasize glucose checks; educate on sweating and confusion as alternate cues |
| Peripheral coldness / Raynaud symptoms | Class effect | Assess extremity perfusion; notify prescriber if painful or cyanotic |
| Sleep disturbance / vivid dreams | Central nervous system effect reported with beta blockers | Assess timing of dose; notify prescriber if distressing or persistent |
| Hyperkalemia (with Ziac) | Thiazide combination may affect electrolytes | Review BMP trends and symptoms of electrolyte imbalance |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Beta-blocker overdose causes bradycardia, hypotension, bronchospasm, and heart failure. There is no single specific antidote listed in the reviewed prescribing information.
Management per labeling
- Stop bisoprolol; monitor in a higher-acuity setting with IV access
- Bradycardia: IV atropine; if inadequate, isoproterenol cautiously or transvenous pacing
- Hypotension: IV fluids and vasopressors; IV glucagon may be useful per labeling
- Heart block (second or third degree): isoproterenol infusion or transvenous pacemaker
- Congestive heart failure: conventional therapy (e.g., digitalis, furosemide, inotropic agents per prescriber)
- Bronchospasm: isoproterenol and/or aminophylline
- Hypoglycemia: IV glucose
- Limited data suggest bisoprolol is not dialyzable
| Overdose manifestation | Intervention (labeling summary) |
|---|---|
| Severe bradycardia | IV atropine; isoproterenol or transvenous pacing if refractory |
| Hypotension | IV fluids; vasopressors; IV glucagon may be useful |
| Bronchospasm | Isoproterenol and/or aminophylline |
| Heart failure | Digitalization, diuretics, inotropic and vasodilator agents per prescriber |
| Drug removal | Not dialyzable per limited labeling data |
On a small screen, swipe or scroll sideways to see the full table.
Contact local poison control or medical toxicology services for overdose guidance per facility protocol and local emergency guidance.
Look-alike / sound-alike and error prevention
- Bisoprolol vs betaxolol—similar names; read full generic name on MAR and teach-back
- Zebeta vs Ziac—combination contains hydrochlorothiazide; duplicate diuretic risk if another thiazide is ordered
- Multiple beta blockers—bisoprolol plus other beta blockers (e.g., atenolol) from different providers—duplicate therapy risk
- Bisoprolol vs bisoprolol-HCTZ—verify single-entity versus combination tablet
- Dose strength—2.5 mg vs 5 mg vs 10 mg tablets; renal/hepatic impairment starts at 2.5 mg
- Abrupt stop—patient may confuse hold for stop; document taper orders clearly
High-risk populations
| Population | Considerations |
|---|---|
| Coronary artery disease / post-MI | Never discontinue abruptly; taper gradually with monitoring per prescriber guidance; rebound angina and MI reported |
| Older adults | Start 25 mg daily; higher risk of bradycardia and hypotension; fall risk with dizziness |
| Renal or hepatic impairment | Initial 2.5 mg/day; cautious titration when CrCl <40 mL/min or hepatic disease |
| Diabetes mellitus | Masks hypoglycemia tachycardia; monitor glucose closely |
| Reactive airway disease | Use caution; bronchospasm possible despite cardioselectivity |
| Pregnancy / lactation | Pregnancy Category C per labeling—use only if benefit justifies fetal risk; LactMed notes low milk levels at 5 mg/day but moderate accumulation risk in neonates—coordinate with prescriber |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Apical pulse (full minute), blood pressure, and rhythm before each dose and when symptoms change
- Orthostatic vital signs after dose increases or in fall-risk patients
- Renal and hepatic function; electrolytes when diuretics are co-prescribed (Ziac or separate thiazide)
- Blood glucose trends in diabetes; angina frequency and exertional symptoms in CAD
Document
- Heart rate, blood pressure, and whether dose was held with prescriber notification
- Taper plan when discontinuing; patient education on not stopping abruptly
- Any bronchospasm, syncope, or angina after missed doses
| Parameter | Typical nursing frequency | Action threshold (verify local protocol) |
|---|---|---|
| Apical pulse | Before each dose; when symptoms change | Hold and notify if below prescriber minimum (often <60/min in adults) |
| Blood pressure | Before each dose; orthostatics after dose changes | Hold for symptomatic hypotension or SBP below protocol limit |
| Rhythm | When pulse irregular or patient reports palpitations | Obtain ECG or rhythm strip; hold for new AV block |
| Creatinine / eGFR | Per admission and when renal status changes | Pharmacy review when eGFR declines toward dose-cap ranges |
| Blood glucose | Per diabetes plan when on insulin or sulfonylureas | Teach alternate hypoglycemia cues when beta blocker masks tachycardia |
| Angina symptoms | Each shift in CAD; after missed doses | Escalate rest angina or increasing frequency—possible withdrawal or undertreatment |
On a small screen, swipe or scroll sideways to see the full table.
Patient teaching
- Take at the same time daily; do not double doses if one is missed—call the clinic for guidance
- Never stop suddenly if you have heart disease or angina; prescriber will taper the dose
- Check pulse before taking if instructed; report heart rate below your prescriber limit, fainting, or new wheezing
- Rise slowly from sitting or lying down to reduce dizziness
- If you have diabetes, monitor blood glucose as directed—this medicine can hide shaking and fast heartbeat during low sugar
- Inform all clinicians and dentists that you take a beta blocker before procedures requiring epinephrine or certain anesthetics
| Teach-back topic | Patient should be able to say |
|---|---|
| Pulse check | How to count pulse for one minute and when to call if too slow |
| Missed doses | Do not double; call clinic if several doses missed |
| Stopping therapy | Prescriber must taper—never stop suddenly if heart disease |
| Diabetes | Sweating or confusion may still occur; check glucose as directed |
| When to seek care | Fainting, severe dizziness, chest pain, new wheezing |
On a small screen, swipe or scroll sideways to see the full table.
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Apical pulse below prescriber or protocol minimum (commonly <60 beats/min in adults—verify institutional parameters)
- Systolic blood pressure below hold threshold or symptomatic hypotension
- New second- or third-degree AV block, sick sinus syndrome, or symptomatic bradycardia on monitor
- Active bronchospasm or severe reactive airway exacerbation
- Patient self-discontinued or multiple doses missed in CAD—do not restart full dose without prescriber/pharmacy plan
- Order exceeds renal/hepatic maximum for documented creatinine clearance or hepatic impairment
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
| Common institutional hold example | Nursing action |
|---|---|
| Apical pulse <60/min | Hold dose; notify prescriber; recheck in 30–60 minutes per protocol |
| SBP <100 mmHg or symptomatic low BP | Hold; orthostatic assessment; notify prescriber |
| New heart block or irregular pulse | Hold; obtain rhythm strip; urgent notification |
| Active wheeze / bronchospasm | Hold; treat respiratory symptoms; notify prescriber |
On a small screen, swipe or scroll sideways to see the full table.
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Pulse check | Apical count full 60 seconds—radial pulse may be irregular or weak with block |
| Timing | Once daily; align with home routine on discharge teaching |
| Perioperative | Continue or hold per anesthesia/prescriber plan—abrupt withdrawal risky in CAD |
| Ziac | Includes hydrochlorothiazide—monitor potassium and orthostatics |
| Commonly missed | Second beta blocker on home list; patient stops drug when BP looks normal |
| Ask pharmacy when | Renal dose adjustment, drug interaction with nodal agents, or taper schedule after MI/angina |
On a small screen, swipe or scroll sideways to see the full table.
Clinical practice integration and workflow
Bisoprolol is a once-daily oral beta blocker whose safety hinges on vital signs before administration and disciplined tapering at discontinuation—not on complex infusion technique.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and right apical pulse and blood pressure
- Compare heart rate to hold parameters on the MAR and nursing protocol
- Screen for duplicate beta-blocker therapy on MAR and home med list
- Verify renal/hepatic dose cap when creatinine clearance is below 40 mL/min or hepatic impairment is present
2. High-alert and safety badge
Not an ISMP high-alert medication, but bradycardia and withdrawal ischemia require the same vital-sign disciplineTreat pre-dose pulse and blood pressure checks as non-negotiable even when the drug is not on your facility high-alert list.
3. Clinical workflow: hold and question rules
- If pulse or blood pressure is below threshold, hold and notify before giving—do not administer and document later
- If the patient skipped several doses, clarify restart vs taper with pharmacy—especially post-MI or angina
- Before surgery, confirm perioperative beta-blocker plan with anesthesia and cardiology
4. Critical teach-back questions
- “What should you do if your pulse is too slow before your pill?” (Hold and call prescriber/clinic per instructions—do not take the dose.)
- “Can you stop this medicine when your blood pressure looks good?” (No—prescriber must taper; sudden stop can cause chest pain or heart attack in heart disease.)
5. Care coordination
Pharmacist: Renal/hepatic dosing, interaction review with digoxin and calcium channel blockers, taper schedules
Prescriber / cardiology: Symptomatic bradycardia, heart block, failed angina control, or perioperative beta-blocker decisions
🧠 Quick mental checklist
- Apical pulse for full minute and BP before this dose?
- Below hold heart rate or blood pressure?
- Any nodal drugs (digoxin, diltiazem) increasing block risk?
- Renal function supports current dose cap?
- If stopping therapy, is there a taper—not abrupt discontinuation?
Bisoprolol NCLEX practice questions
This NCLEX-style clinical judgment practice set for bisoprolol uses a tabbed inpatient case (MAR, labs, vitals, nursing notes), then priority action, cue recognition, trend interpretation, matrix urgency sorting, taper judgment, and overdose management cloze—recognise cues → analyse → prioritise → act → evaluate outcomes (bradycardia vs safe parameters vs ischemic rebound after abrupt stop).
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Bisoprolol 5 mg PO daily — due 0800; held yesterday for HR 52
- Digoxin 0.125 mg PO daily — given 0700
- Furosemide 20 mg PO daily — given 0700
- Lisinopril 10 mg PO daily — given 0700
- Creatinine 1.4 mg/dL (baseline 1.1); eGFR estimated 38 mL/min
- Potassium 4.2 mEq/L; glucose 142 mg/dL fasting
- Prior BMP stable; pharmacy note: renal/hepatic dose review for bisoprolol
- Apical pulse 58/min regular; BP 118/72 supine; BP 104/68 standing
- SpO2 97% on room air; denies chest pain; mild lightheadedness on standing
- Hold parameters on chart: give if apical pulse ≥60 and SBP ≥100
- History: hypertension, stable heart failure, prior angina; no pacemaker
- 0700: Patient reports skipped two home doses while traveling—restarted hospital bisoprolol yesterday, then held for bradycardia
- 0730: Asks whether to take morning pill because BP “looks good”
Answer key & rationale
Frequently asked questions
Common nursing questions about bisoprolol focus on pre-dose pulse checks, hold parameters, safe tapering, expected adverse effects, and overdose management when no single antidote exists.
What should I check before giving bisoprolol?
Count apical pulse for a full minute and obtain blood pressure (and orthostatic measurements when indicated). Review hold parameters on the MAR, check for nodal drugs such as digoxin or verapamil/diltiazem, and confirm renal/hepatic function supports the ordered dose (often 2.5 mg start when CrCl is below 40 mL/min). Document findings before administration.
When should a nurse hold bisoprolol?
Hold when apical pulse or blood pressure falls below prescriber or protocol limits, when new second- or third-degree AV block or symptomatic bradycardia is present, during active bronchospasm, or when signs of worsening heart failure appear. Also hold and clarify if the patient missed multiple doses—do not restart full dose without prescriber/pharmacy guidance.
Can bisoprolol be stopped suddenly?
No. Prescribing information advises tapering over about one week with monitoring. Abrupt cessation in coronary artery disease can worsen angina or cause myocardial infarction or ventricular arrhythmias—even patients treated only for hypertension may need gradual withdrawal.
What adverse effects matter most with bisoprolol?
Bradycardia, hypotension, fatigue, dizziness, heart block, bronchospasm in reactive airways, and masked hypoglycemia symptoms in diabetes are the highest-impact effects for bedside nurses.
Is there an antidote for bisoprolol overdose?
There is no single specific antidote in the reviewed prescribing information. Management is supportive: IV atropine, isoproterenol or pacing for bradycardia or heart block, vasopressors and glucagon for hypotension, bronchodilators for bronchospasm, and IV glucose for hypoglycemia. Limited data suggest bisoprolol is not dialyzable. Contact local poison control or medical toxicology per facility protocol.
References
-
U.S. National Library of Medicine. BISOPROLOL FUMARATE tablet — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d540ef44-9016-9d66-e053-2a95a90a16a9
-
U.S. Food and Drug Administration. ZEBETA (bisoprolol fumarate) tablets — Prescribing information.https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
-
Drugs and Lactation Database (LactMed). Bisoprolol. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501144/
-
American Heart Association. Types of blood pressure medications — Beta blockers.https://www.heart.org/en/health-topics/high-blood-pressure/changes-you-can-make-to-manage-high-blood-pressure/types-of-blood-pressure-medications
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.
Last content review: May 25, 2026.